Skip to main content
. 2021 Apr 23;39(17):1842–1855. doi: 10.1200/JCO.21.00306

FIG 2.

FIG 2.

Efficacy: PFS in (A) ITT population and (B) PD-L1+ population; OS in (C) ITT population and (D) PD-L1+ population. CP, carboplatin plus paclitaxel; HR, hazard ratio; ITT, intention-to-treat; NE, not evaluable; OS, overall survival; PD-L1, programmed death ligand-1; PFS, progression-free survival.